O'Ddonnell James S, Hinkson Larry, McCarthy Andrew, Manning Richard, Khan Ayesha, Laffan Michael A
National Centre for Hereditary Coagulation Disorders, St James's Hospital, Dublin, Ireland.
Blood Coagul Fibrinolysis. 2006 Apr;17(3):217-20. doi: 10.1097/01.mbc.0000220246.20036.f6.
Quantitative antithrombin deficiency constitutes an important risk factor for venous thromboembolism, stillbirth, and other complications of pregnancy. Studies suggest, however, that individuals heterozygous for missense mutations involving the heparin-binding site of antithrombin do not have a significantly increased thrombotic risk. Owing to the rarity of such mutations, it remains unclear whether any specific heparin-binding site defects might be associated with thrombotic potential. We report here the case of a pregnant woman with an exceptionally rare Type II heparin-binding site antithrombin variant. This case highlights the difficult issues that are associated with the management of Type II antithrombin deficiency during pregnancy.
定量抗凝血酶缺乏是静脉血栓栓塞、死产及其他妊娠并发症的重要危险因素。然而,研究表明,抗凝血酶肝素结合位点错义突变的杂合子个体血栓形成风险并未显著增加。由于此类突变罕见,尚不清楚是否有任何特定的肝素结合位点缺陷可能与血栓形成潜力相关。我们在此报告一例患有极其罕见的II型肝素结合位点抗凝血酶变异体的孕妇病例。该病例凸显了妊娠期间II型抗凝血酶缺乏管理所涉及的棘手问题。